skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Clinical efficacy of subthreshold micropulse laser combined with anti-VEGF drugs in the treatment of diabetic macular edema: A meta-analysis

Medicine (Baltimore), 2024-02, Vol.103 (5), p.e34583-e34583 [Peer Reviewed Journal]

Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. ;Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. 2024 ;ISSN: 0025-7974 ;EISSN: 1536-5964 ;DOI: 10.1097/MD.0000000000034583 ;PMID: 38306515

Full text available

Citations Cited by
  • Title:
    Clinical efficacy of subthreshold micropulse laser combined with anti-VEGF drugs in the treatment of diabetic macular edema: A meta-analysis
  • Author: Xu, Dahua ; Zhu, Ting ; Huang, Lin ; Wang, Xiaolin ; Chen, Mei
  • Subjects: Diabetes Mellitus - drug therapy ; Diabetic Retinopathy - drug therapy ; Diabetic Retinopathy - surgery ; Humans ; Lasers ; Macular Edema - drug therapy ; Macular Edema - etiology ; Macular Edema - surgery ; Randomized Controlled Trials as Topic ; Ranibizumab - therapeutic use ; Systematic Review and Meta-Analysis ; Treatment Outcome ; Vascular Endothelial Growth Factor A - therapeutic use ; Vascular Endothelial Growth Factors - therapeutic use
  • Is Part Of: Medicine (Baltimore), 2024-02, Vol.103 (5), p.e34583-e34583
  • Description: To systematically evaluate the efficacy and safety of subthreshold micropulse laser (SML) combined with anti-vascular endothelial growth factor (VEGF) drugs for the treatment of diabetic macular edema (DME). The randomized controlled trials on SML combined with anti-VEGF drugs for DME were retrieved from China National Knowledge Infrastructure, Wan Fang Data, VIP Data, Sino Med (China Biomedical Literature Database), PubMed, Web of Science, The Cochrane Library, and Embase by computer from inception to April 19, 2022. The observation group was treated with SML combined with anti-VEGF drugs, while the control group was treated with anti-VEGF agents alone or SML. And the references of the included literature were manually searched. The Meta-analysis was performed using Revman 5.4 and STATA SE 15. This study finally included 15 randomized controlled trials involving 891 eyes for Meta-analysis. The results showed that there was no statistically significant difference between the 2 groups in best-corrected visual acuity at 1, 3, 6, 9, and 12 months after treatment. There was no statistical difference between the 2 groups in central macular thickness (CMT) at 1, 3, and 6 months after treatment (P > .05). CMT in the observation group was lower than that in the control group at 9 and 12 months (P < .05). There was no statistical difference between the 2 groups in total macular volume at 3, 6, 9, and 12 months in CMT (P > .05). The number of anti-VEGF drugs injections in the observation was lower than that in the control group (P < .05). The occurrence of complications between the 2 groups was not statistically significant difference (P > .05). SML in combination with anti-VEGF drugs in patients with DME are comparable in reducing the number of anti-VEGF drugs injections and CMT, thereby reducing the financial burden on patients. It does not differ in best-corrected visual acuity and total macular volume.
  • Publisher: United States: Lippincott Williams & Wilkins
  • Language: English
  • Identifier: ISSN: 0025-7974
    EISSN: 1536-5964
    DOI: 10.1097/MD.0000000000034583
    PMID: 38306515
  • Source: IngentaConnect
    Journals@Ovid Open Access Journal Collection Rolling
    DOAJ Directory of Open Access Journals
    Wolters Kluwer Open Health
    MEDLINE
    PubMed Central
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait